On Wednesday, Theratechnologies Inc (NASDAQ:THTX) reported second-quarter 2024 sales of $22.02 million, up 25.5% year over year, beating the consensus of $21.71 million. For the second quarter, net sales of EGRIFTA SV were $16.2 million, up 49.3% year over year, due to strong demand for the product, combined with weaker than usual sales in Q2 of last year stemming from drawdowns in inventory early in the second quarter of 2023. EGRIFTA SV is an injectable prescription medicine used to reduce excess abdominal fat in adults with HIV and lipodystrophy. Trogarzo’s net sales in the second quarter reached $5.82 million, down 13.1% year over year, primarily due to competitive pressures in the multi-drug-resistant segment of the HIV-1 market. Trogarzo is used ...